TDMS Study 05109-12 Pathology Tables
INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
TRIETHANOLAMINE
NTP Experiment-Test: 05109-12 Report: PEIRPT03
Study Type: CHRONIC Date: 05/20/95
Route: DERMAL,SOLUTION Time: 00:11:45
Facility: Battelle Columbus Laboratory
Chemical CAS #: 102-71-6
Lock Date: 08/21/92
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05109-12 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/20/95
Route: DERMAL,SOLUTION Time: 00:11:45
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 60 60 60 60
Scheduled Sacrifice 10 10 10 10
Early Deaths
Moribund Sacrifice 7 4 5 11
Natural Death 4 6 7 2
Survivors
Terminal Sacrifice 38 40 38 37
Natural Death 1
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (60) (60) (60) (60)
Inflammation, Chronic Active 1 (2%)
Intestine Small, Jejunum (60) (60) (60) (60)
Peyer's Patch, Hyperplasia, Lymphoid 2 (3%)
Liver (60) (60) (60) (60)
Basophilic Focus 2 (3%) 2 (3%) 1 (2%)
Clear Cell Focus 1 (2%) 1 (2%) 1 (2%)
Congestion 1 (2%)
Cytoplasmic Alteration 1 (2%)
Eosinophilic Focus 11 (18%) 10 (17%) 18 (30%) 17 (28%)
Fatty Change 1 (2%)
Hematopoietic Cell Proliferation 1 (2%)
Hepatodiaphragmatic Nodule 1 (2%)
Hypertrophy 1 (2%)
Infiltration Cellular, Lymphocyte 2 (3%)
Inflammation, Chronic Active 1 (2%) 1 (2%)
Karyomegaly 1 (2%)
Leukocytosis 1 (2%)
Necrosis 2 (3%) 3 (5%) 2 (3%) 1 (2%)
Kupffer Cell, Hyperplasia 1 (2%)
Mesentery (2) (5) (5) (5)
Fat, Infiltration Cellular, Lymphocyte 1 (20%)
Fat, Inflammation, Chronic 2 (100%) 4 (80%) 3 (60%) 3 (60%)
Pancreas (60) (60) (60) (60)
Cyst 1 (2%)
Inflammation, Chronic Active 1 (2%) 1 (2%)
Acinus, Atrophy 4 (7%) 2 (3%) 1 (2%)
Artery, Inflammation, Chronic 1 (2%)
Duct, Cyst 1 (2%)
Stomach, Forestomach (60) (60) (60) (60)
Acanthosis 1 (2%) 1 (2%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 05109-12 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/20/95
Route: DERMAL,SOLUTION Time: 00:11:45
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Stomach, Glandular (60) (60) (60) (60)
Hyperplasia 1 (2%) 1 (2%) 1 (2%)
Inflammation, Chronic Active 1 (2%)
Pigmentation 1 (2%) 1 (2%)
Ulcer 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60) (60) (60)
Artery, Thrombosis 1 (2%)
Coronary Artery, Inflammation, Chronic 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (59) (60) (60)
Hyperplasia 1 (2%)
Hypertrophy 3 (5%) 2 (3%) 3 (5%) 1 (2%)
Infiltration Cellular, Lymphocyte 1 (2%)
Necrosis 1 (2%)
Capsule, Accessory Adrenal Cortical Nodule 2 (3%) 2 (3%)
Capsule, Cyst 1 (2%) 1 (2%)
Capsule, Spindle Cell, Hyperplasia 1 (2%) 1 (2%)
Adrenal Medulla (60) (60) (60) (60)
Cyst 1 (2%)
Hyperplasia 1 (2%) 3 (5%) 3 (5%)
Pituitary Gland (54) (59) (59) (59)
Pars Distalis, Angiectasis 1 (2%)
Pars Distalis, Cyst 1 (2%) 2 (3%) 1 (2%)
Pars Distalis, Hyperplasia 3 (6%) 7 (12%) 8 (14%) 5 (8%)
Pars Intermedia, Hyperplasia 1 (2%)
Rathke's Cleft, Cyst 1 (2%)
Rathke's Cleft, Hemorrhage 1 (2%)
Thyroid Gland (60) (60) (60) (60)
Infiltration Cellular, Lymphocyte 1 (2%)
Inflammation, Chronic Active 1 (2%)
Follicle, Cyst 1 (2%) 2 (3%)
Follicular Cell, Hyperplasia 23 (38%) 20 (33%) 18 (30%) 27 (45%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 05109-12 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/20/95
Route: DERMAL,SOLUTION Time: 00:11:45
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (58) (58) (56) (58)
Inflammation, Chronic 1 (2%)
Duct, Ectasia 3 (5%) 1 (2%) 2 (4%) 3 (5%)
Ovary (59) (60) (59) (60)
Atrophy 34 (58%) 37 (62%) 34 (58%) 29 (48%)
Cyst 1 (2%)
Thrombosis 2 (3%) 2 (3%) 1 (2%)
Follicle, Cyst 15 (25%) 19 (32%) 18 (31%) 14 (23%)
Follicle, Cyst, Multiple 1 (2%)
Periovarian Tissue, Cyst 1 (2%) 1 (2%)
Periovarian Tissue, Infiltration Cellular,
Lymphocyte 1 (2%)
Periovarian Tissue, Inflammation, Chronic
Active 1 (2%)
Uterus (60) (60) (59) (60)
Hemorrhage 1 (2%)
Infiltration Cellular, Lymphocyte 1 (2%)
Inflammation, Chronic 1 (2%)
Endometrium, Hyperplasia, Cystic, Glandular 57 (95%) 58 (97%) 56 (95%) 53 (88%)
Lymphatic, Ectasia 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (60) (60) (60)
Myelofibrosis 7 (12%) 16 (27%) 4 (7%) 7 (12%)
Myeloid Cell, Atrophy 1 (2%)
Lymph Node (4) (8) (6) (9)
Mediastinal, Hyperplasia, Lymphoid 1 (25%) 1 (17%)
Lymph Node, Mandibular (57) (59) (59) (59)
Hyperplasia, Lymphoid 1 (2%) 2 (3%) 1 (2%)
Lymph Node, Mesenteric (54) (59) (56) (59)
Hematopoietic Cell Proliferation 1 (2%)
Hyperplasia, Lymphoid 1 (2%) 1 (2%)
Spleen (60) (60) (60) (60)
Hematopoietic Cell Proliferation 3 (5%) 9 (15%) 3 (5%) 6 (10%)
Hyperplasia, Lymphoid 5 (8%) 5 (8%)
Necrosis 1 (2%)
Thymus (55) (57) (58) (58)
Atrophy 19 (35%) 28 (49%) 28 (48%) 22 (38%)
Cyst 1 (2%)
Hyperplasia, Lymphoid 1 (2%) 2 (3%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 05109-12 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/20/95
Route: DERMAL,SOLUTION Time: 00:11:45
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (58) (57) (60) (57)
Hyperplasia, Glandular 1 (2%)
Skin (60) (60) (60) (60)
Acanthosis 1 (2%)
Inguinal, Inflammation, Chronic 1 (2%)
Site of Application-No Mass, Acanthosis 3 (5%) 1 (2%) 5 (8%)
Site of Application-No Mass, Inflammation,
Chronic 2 (3%) 2 (3%) 8 (13%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (60) (60) (60) (60)
Vertebra, Coccygeal, Fracture 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (60) (60) (60)
Compression 3 (5%) 3 (5%) 1 (2%) 1 (2%)
Hemorrhage 2 (3%)
Medulla, Hemorrhage 1 (2%)
Peripheral Nerve (2) (1) (1)
Sciatic, Degeneration 1 (100%)
Spinal Cord (2) (1) (1)
Nerve, Degeneration 1 (50%) 1 (100%) 1 (100%)
White Matter, Degeneration 1 (100%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (60) (59)
Hemorrhage, Focal 1 (2%)
Inflammation, Chronic Active 1 (2%) 1 (2%)
Mineralization, Focal 1 (2%)
Alveolar Epithelium, Hyperplasia 1 (2%) 1 (2%)
Alveolar Epithelium, Hyperplasia, Macrophage 1 (2%)
Pleura, Hyperplasia 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1) (1) (1)
Internal Ear, Hyperplasia, Glandular 1 (100%)
Harderian Gland (1) (2) (1)
Acinus, Hyperplasia 1 (50%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 05109-12 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/20/95
Route: DERMAL,SOLUTION Time: 00:11:45
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60) (60) (60)
Amyloid Deposition 1 (2%)
Inflammation, Chronic Active 1 (2%)
Nephropathy, Chronic 22 (37%) 30 (50%) 30 (50%) 25 (42%)
Cortex, Cyst 1 (2%)
Cortex, Infarct 3 (5%) 2 (3%)
Pelvis, Inflammation, Acute 1 (2%)
Renal Tubule, Hyperplasia, Cystic 1 (2%)
Renal Tubule, Necrosis 1 (2%)
Urinary Bladder (60) (60) (59) (60)
Inflammation, Chronic Active 1 (2%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 05109-12 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/20/95
Route: DERMAL,SOLUTION Time: 00:11:45
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 60 60 60 60
Scheduled Sacrifice 10 10 10 10
Early Deaths
Moribund Sacrifice 2 5 3 6
Natural Death 2 5 8 3
Survivors
Terminal Sacrifice 46 39 39 41
Natural Death 1
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (59) (58) (58) (59)
Cyst 1 (2%)
Intestine Small, Jejunum (60) (60) (60) (60)
Peyer's Patch, Hyperplasia, Lymphoid 1 (2%)
Liver (60) (60) (60) (60)
Basophilic Focus 7 (12%) 3 (5%) 4 (7%) 3 (5%)
Clear Cell Focus 13 (22%) 11 (18%) 7 (12%) 5 (8%)
Congestion 1 (2%)
Cyst 1 (2%)
Cytoplasmic Alteration 10 (17%) 17 (28%) 10 (17%) 16 (27%)
Eosinophilic Focus 10 (17%) 17 (28%) 11 (18%) 24 (40%)
Fatty Change 1 (2%)
Hematopoietic Cell Proliferation 1 (2%) 1 (2%) 1 (2%)
Infiltration Cellular, Lymphocyte 1 (2%)
Karyomegaly 13 (22%) 18 (30%) 10 (17%) 18 (30%)
Mixed Cell Focus 2 (3%) 3 (5%)
Necrosis 1 (2%) 2 (3%)
Thrombosis 1 (2%)
Bile Duct, Hyperplasia 2 (3%) 2 (3%) 1 (2%)
Hepatocyte, Cytoplasmic Alteration 3 (5%) 1 (2%) 1 (2%) 2 (3%)
Hepatocyte, Cytoplasmic Alteration, Focal 1 (2%)
Hepatocyte, Necrosis 1 (2%)
Hepatocyte, Vacuolization Cytoplasmic,
Multifocal 4 (7%) 6 (10%) 3 (5%) 6 (10%)
Kupffer Cell, Hyperplasia 1 (2%)
Oval Cell, Hyperplasia 12 (20%) 15 (25%) 10 (17%) 19 (32%)
Mesentery (3) (1)
Fat, Inflammation, Chronic 2 (67%)
Pancreas (60) (60) (60) (60)
Infiltration Cellular, Histiocyte 1 (2%)
Acinus, Atrophy 3 (5%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
NTP Experiment-Test: 05109-12 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/20/95
Route: DERMAL,SOLUTION Time: 00:11:45
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Artery, Inflammation, Chronic 1 (2%)
Duct, Cyst 1 (2%)
Stomach, Forestomach (60) (59) (60) (60)
Acanthosis 1 (2%) 1 (2%) 1 (2%)
Ulcer 2 (3%)
Stomach, Glandular (60) (60) (60) (60)
Dysplasia 2 (3%)
Hyperplasia 1 (2%)
Pigmentation 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60) (60) (60)
Degeneration, Chronic 1 (2%) 1 (2%) 1 (2%)
Atrium, Thrombosis 1 (2%)
Coronary Artery, Polyarteritis, Chronic 2 (3%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (60) (60) (60)
Angiectasis 1 (2%)
Developmental Malformation 1 (2%) 1 (2%)
Hyperplasia 1 (2%) 2 (3%) 1 (2%) 3 (5%)
Hypertrophy 17 (28%) 14 (23%) 16 (27%) 7 (12%)
Necrosis 1 (2%) 2 (3%)
Thrombosis 1 (2%)
Vacuolization Cytoplasmic 7 (12%) 1 (2%) 2 (3%)
Capsule, Accessory Adrenal Cortical Nodule 1 (2%) 2 (3%) 1 (2%)
Capsule, Cyst 1 (2%)
Capsule, Hyperplasia 1 (2%)
Capsule, Spindle Cell, Hyperplasia 10 (17%) 4 (7%) 7 (12%) 4 (7%)
Adrenal Medulla (60) (60) (60) (60)
Hyperplasia 2 (3%) 3 (5%) 1 (2%)
Necrosis 1 (2%)
Parathyroid Gland (55) (52) (56) (54)
Cyst 1 (2%) 1 (2%)
Pituitary Gland (58) (59) (56) (59)
Pars Distalis, Cyst 2 (3%) 1 (2%) 1 (2%) 3 (5%)
Pars Distalis, Hyperplasia 2 (3%) 1 (2%) 1 (2%)
Thyroid Gland (60) (60) (60) (60)
Infiltration Cellular, Lymphocyte 1 (2%)
Polyarteritis, Chronic 1 (2%)
Follicle, Cyst 1 (2%)
Follicular Cell, Hyperplasia 14 (23%) 12 (20%) 10 (17%) 9 (15%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 8
NTP Experiment-Test: 05109-12 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/20/95
Route: DERMAL,SOLUTION Time: 00:11:45
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (60) (60) (60) (60)
Granuloma Sperm 1 (2%) 2 (3%) 1 (2%) 2 (3%)
Artery, Inflammation, Chronic 1 (2%)
Preputial Gland (60) (60) (60) (60)
Inflammation, Chronic 2 (3%) 1 (2%) 2 (3%)
Inflammation, Chronic Active 1 (2%) 2 (3%)
Duct, Ectasia 36 (60%) 43 (72%) 31 (52%) 24 (40%)
Prostate (60) (60) (60) (60)
Infiltration Cellular, Histiocyte 1 (2%)
Inflammation, Chronic 1 (2%) 1 (2%)
Seminal Vesicle (50) (50) (50) (50)
Inflammation, Chronic 1 (2%) 1 (2%)
Artery, Inflammation, Chronic 1 (2%)
Testes (60) (60) (60) (60)
Congestion 1 (2%)
Germinal Epithelium, Atrophy 1 (2%) 1 (2%)
Germinal Epithelium, Mineralization 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (59) (58) (59)
Myelofibrosis 1 (2%) 1 (2%)
Lymph Node, Mandibular (57) (57) (57) (57)
Hyperplasia, Lymphoid 1 (2%)
Lymph Node, Mesenteric (56) (57) (53) (55)
Fibrosis 1 (2%)
Hematopoietic Cell Proliferation 1 (2%) 3 (5%) 1 (2%) 1 (2%)
Spleen (60) (60) (60) (60)
Congestion 1 (2%)
Hematopoietic Cell Proliferation 4 (7%) 6 (10%) 4 (7%) 8 (13%)
Thymus (53) (46) (57) (52)
Atrophy 14 (26%) 25 (54%) 19 (33%) 16 (31%)
Cyst 1 (2%)
Infiltration Cellular, Histiocyte 1 (2%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 9
NTP Experiment-Test: 05109-12 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/20/95
Route: DERMAL,SOLUTION Time: 00:11:45
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (60) (60) (60) (60)
Ulcer 2 (3%)
Hair Follicle, Sebaceous Gland, Site of
Application-No Mass, Atrophy 1 (2%) 15 (25%)
Inguinal, Acanthosis 1 (2%)
Inguinal, Inflammation, Chronic 2 (3%)
Inguinal, Ulcer 1 (2%)
Inguinal, Subcutaneous Tissue, Edema 1 (2%)
Site of Application-No Mass, Acanthosis 2 (3%) 2 (3%) 7 (12%) 17 (28%)
Site of Application-No Mass, Inflammation,
Chronic 2 (3%) 9 (15%) 16 (27%)
Site of Application-No Mass, Ulcer 1 (2%) 2 (3%) 2 (3%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (60) (59) (58) (59)
Cranium, Hyperostosis 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (60) (60) (60)
Pons, Necrosis, Chronic, Focal 1 (2%)
Peripheral Nerve (1) (1) (1)
Sciatic, Degeneration 1 (100%) 1 (100%)
Spinal Cord (1) (1) (3) (1)
Nerve, Degeneration 1 (33%) 1 (100%)
White Matter, Degeneration 1 (100%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (60) (60)
Inflammation, Chronic 1 (2%) 2 (3%)
Alveolar Epithelium, Hyperplasia 3 (5%) 4 (7%) 2 (3%) 2 (3%)
Alveolar Epithelium, Hyperplasia, Macrophage 1 (2%) 1 (2%)
Alveolus, Hemorrhage, Multifocal 1 (2%)
Mediastinum, Infiltration Cellular,
Histiocyte 1 (2%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 10
NTP Experiment-Test: 05109-12 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/20/95
Route: DERMAL,SOLUTION Time: 00:11:45
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (3) (1)
Cornea, Inflammation, Chronic 3 (100%)
Cornea, Inflammation, Chronic, Proliferative 1 (100%)
Harderian Gland (4) (5) (6) (1)
Hyperplasia 1 (17%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60) (60) (60)
Hydronephrosis 2 (3%) 1 (2%)
Metaplasia, Osseous 1 (2%)
Mineralization 1 (2%)
Nephropathy, Chronic 55 (92%) 54 (90%) 55 (92%) 56 (93%)
Cortex, Cyst 4 (7%) 4 (7%) 2 (3%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------